2015 in oncology

The approvals rows on treatment records: region, year and indication.

• 2015Alectinib approved in US

  ALK+ NSCLC after crizotinib

• 2015Carfilzomib approved in US

  With lenalidomide-dexamethasone; with dexamethasone (ENDEAVOR)

• 2015Ceritinib approved in EU

  Conditional May 2015; full approval 2017

• 2015Cobimetinib approved in US

  BRAF V600 melanoma with vemurafenib

• 2015Daratumumab approved in US

  Relapsed myeloma after ≥3 lines

• 2015Dinutuximab (ch14.18) / dinutuximab beta approved in US

  High-risk neuroblastoma after at least partial response to induction, with GM-CSF, IL-2 and isotretinoin

• 2015Elotuzumab approved in US

  Multiple myeloma after 1-3 prior therapies, with lenalidomide-dexamethasone

• 2015Filgrastim (G-CSF) approved in US

  First US biosimilar (Zarxio, filgrastim-sndz); further biosimilars 2018 onwards

• 2015Gefitinib approved in US

  First-line NSCLC with EGFR exon 19 del or L858R

• 2015Irinotecan (and liposomal irinotecan) approved in US

  Liposomal irinotecan with 5-FU/LV in metastatic pancreatic cancer after gemcitabine

• 2015Ixazomib approved in US

  Multiple myeloma after ≥1 prior therapy, with lenalidomide and dexamethasone

• 2015Lenalidomide approved in US

  Newly diagnosed myeloma with dexamethasone

• 2015Lenvatinib approved in US

  Radioiodine-refractory thyroid cancer

• 2015Liposomal irinotecan approved in US

  Metastatic pancreatic adenocarcinoma after gemcitabine-based therapy, with fluorouracil and leucovorin (NAPOLI-1).

• 2015Necitumumab approved in US

  First-line metastatic squamous NSCLC with gemcitabine and cisplatin

• 2015Netupitant and palonosetron approved in EU

  Acute and delayed nausea and vomiting with highly and moderately emetogenic chemotherapy (Akynzeo)

• 2015Nintedanib approved in England (NICE)

  Locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology progressing after first-line chemotherapy, with docetaxel.

• 2015Optune / Optune Pax (TTFields) approved in EU

  CE mark (GBM); pancreatic and NSCLC CE marks 2024-26

• 2015Osimertinib approved in US

  EGFR T790M NSCLC

• 2015Palbociclib approved in US

  HR+/HER2- advanced breast cancer with endocrine therapy

• 2015Panobinostat approved in EU

  Relapsed/refractory multiple myeloma

• 2015Panobinostat approved in US

  Multiple myeloma after ≥2 regimens including bortezomib and an IMiD. Withdrawn 2021

• 2015PD-L1 IHC 22C3 pharmDx approved in US

  Companion diagnostic for pembrolizumab in NSCLC (TPS)

• 2015Rolapitant approved in US

  Prevention of delayed nausea and vomiting with emetogenic chemotherapy, in combination with other antiemetics

• 2015Sonidegib approved in EU

  Same

• 2015Sonidegib approved in US

  Locally advanced BCC recurrent after surgery or radiation, or not candidates

• 2015Talimogene laherparepvec approved in US

  Unresectable melanoma with injectable lesions

• 2015Trabectedin approved in US

  Liposarcoma and leiomyosarcoma after anthracycline

• 2015Trifluridine/tipiracil approved in US

  Refractory metastatic colorectal cancer

• 2015Uridine triacetate approved in US

  Emergency treatment after fluorouracil or capecitabine overdose or early-onset severe toxicity within 96 hours

The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.

• 3 February 2015Palbociclib: approval (US)

  Accelerated approval with letrozole: first CDK4/6 inhibitor (PALOMA-1)

• 4 March 2015Nivolumab: approval (US)

  Squamous NSCLC after platinum: first PD-1 in lung cancer

• 10 March 2015Dinutuximab (ch14.18) / dinutuximab beta: approval (US)

  Unituxin (ANBL0032)

• 17 August 2015Brentuximab vedotin: approval (US)

  Post-transplant consolidation in Hodgkin lymphoma (AETHERA)

• September 2015Trifluridine/tipiracil: approval (US)

  RECOURSE

• 1 October 2015Nivolumab: approval (US)

  With ipilimumab, BRAF wild-type melanoma (CheckMate 067)

• 2 October 2015Pembrolizumab: approval (US)

  PD-L1+ NSCLC after platinum

• 5 October 2015Optune / Optune Pax (TTFields): approval (US)

  Newly diagnosed glioblastoma with temozolomide (EF-14)

• 27 October 2015Talimogene laherparepvec: approval (US)

  Unresectable melanoma with injectable lesions (OPTiM): first oncolytic virus approved in the US

• 28 October 2015Ipilimumab: approval (US)

  Adjuvant stage III melanoma (10 mg/kg; later superseded)

• 10 November 2015Vemurafenib: approval (US)

  Cobimetinib approved in combination (coBRIM)

• 13 November 2015Osimertinib: approval (US)

  Accelerated approval, EGFR T790M NSCLC after TKI

• 16 November 2015Daratumumab: approval (US)

  First CD38 antibody

• December 2015Talimogene laherparepvec: approval (EU)

  EMA approval

The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.

• 2015Sakigake designation (Japan)

  Japan, scheme.

The year reported on trial records, with the headline result the record gives.

• 2015A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma reported
  Multiple myelomaPalifermin
• 2015ACNS0122 reported

  74 of 85 evaluable patients responded to induction chemotherapy; three-year progression-free survival 92 percent and overall survival 94.1 percent with craniospinal irradiation, th...

  Central nervous system germ cell tumours (germinoma and non-germinomatous)Brain and spinal cord tumours (all types)Childhood cancers (all types)Carboplatin
• 2015AETHERA reported

  PFS HR 0.57.

  Hodgkin lymphomaRelapsed and refractory classical Hodgkin lymphomaBrentuximab vedotin
• 2015An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma reported
  MelanomaTalimogene laherparepvec
• 2015APT (adjuvant paclitaxel-trastuzumab) reported

  7-year DFS 93%; 10-year RFI 96.3%.

  HER2-positive breast cancerEarly HER2-positive breast cancerPaclitaxel / nab-paclitaxelTrastuzumab
• 2015BOLT reported

  Objective response at 200 mg: 43% in locally advanced and 15% in metastatic basal cell carcinoma (central review).

  Locally advanced and metastatic basal cell carcinomaBasal cell carcinomaSkin cancer (all types)Sonidegib
• 2015CAIRO3 reported

  Progression-free survival 2 of 11.7 against 8.5 months (hazard ratio 0.67), with no loss of quality of life.

  Colorectal cancerCapecitabineBevacizumabCAPOX (capecitabine, oxaliplatin)
• 2015CALGB 40603 (Alliance) reported

  Carboplatin and bevacizumab each raised pCR; at 7.9 years neither improved event-free or overall survival (not powered). pCR: 5-year EFS 85.5% vs 56.6%.

  Triple-negative breast cancer (TNBC)Early triple-negative breast cancerCarboplatinPaclitaxel / nab-paclitaxel
• 2015CHAARTED (E3805) reported

  OS HR 0.61 overall; high-volume HR 0.63; low-volume no benefit.

  Prostate cancerMetastatic hormone-sensitive prostate cancerDocetaxel
• 2015CheckMate 017 reported

  Median overall survival 9.2 against 6.0 months (hazard ratio 0.59, 95 percent confidence interval 0.44 to 0.79), independent of PD-L1 level.

  Squamous cell carcinoma of the lungNon-small-cell lung cancerNivolumabDocetaxel
• 2015CheckMate 025 reported

  Nivolumab improved overall survival and response rate over everolimus in previously treated clear cell renal cell carcinoma; approved in November 2015.

  Clear cell renal cell carcinomaRenal cell carcinomaNivolumabEverolimus
• 2015CheckMate 057 reported

  Median overall survival 12.2 against 9.4 months (hazard ratio 0.73, p=0.002); progression-free survival crossed, favouring docetaxel at the median and nivolumab at one year.

  Adenocarcinoma of the lungNon-small-cell lung cancerNivolumabDocetaxel
• 2015CheckMate 067 reported

  10-year OS 43% vs 37% vs 19%.

  MelanomaAdvanced melanoma (unresectable stage III and stage IV)NivolumabIpilimumab
• 2015Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer reported
  Prostate cancerCinacalcet
• 2015Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy reported
  Breast cancer (all types)
• 2015CONCUR reported

  Median overall survival 8.8 against 6.3 months (hazard ratio 0.55).

  Colorectal cancerRegorafenib
• 2015CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer reported

  One-year overall survival 33 against 28 percent (hazard ratio 0.84, p=0.066, primary endpoint not met); two-year survival 13 against 3 percent (p=0.004).

  Extensive-stage small-cell lung cancer
• 2015DART 01/05 GICOR reported

  Five-year overall survival 95 against 86 percent (hazard ratio 2.48, 95 percent confidence interval 1.31 to 4.68) and biochemical disease-free survival 90 against 81 percent (1.88...

  Prostate cancerLocalised prostate cancer, intermediate riskLocalised prostate cancer, high and very high riskGoserelin / leuprolide (ovarian function suppression)
• 2015EF-14 reported

  OS 20.9 vs 16.0 months, HR 0.63.

  Glioma & glioblastomaOptune / Optune Pax (TTFields)Temozolomide
• 2015Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromega...
  Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinomaPasireotide
• 2015Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma reported
  MelanomaTalimogene laherparepvecSargramostim
• 2015Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial) reported

  3-year OS 80.0% vs 67.5% (HR 0.64); DFS 69.5% vs 45.9%.

  Head and neck squamous cell carcinomaOral cavity cancer (mouth and tongue)Oral tongue and floor of mouth cancerBuccal mucosa and gingivobuccal cancer (oral cancer in India)
• 2015ELM-PC 4 reported

  Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 2...

  Prostate cancerMetastatic castration-resistant prostate cancerOrteronelPrednisone
• 2015EORTC 22881-10882 (boost against no boost) reported

  Twenty-year ipsilateral breast recurrence 12.0 percent with a 16 Gy boost against 16.4 percent without (hazard ratio 0.65), no difference in overall survival, and severe fibrosis 5...

  Breast cancer (all types)HR-positive / HER2-negative breast cancerHER2-positive breast cancerTriple-negative breast cancer (TNBC)
• 2015EORTC 22922/10925 reported

  10-year overall survival 82.3% vs 80.7% (hazard ratio 0.87); fewer distant recurrences and breast cancer deaths.

  HR-positive / HER2-negative breast cancerHER2-positive breast cancerTriple-negative breast cancer (TNBC)Breast cancer (all types)
• 2015Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer reported
  Prostate cancerBicalutamideEstramustineEtoposide
• 2015Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer reported

  Adding radiotherapy to lifelong androgen deprivation in locally advanced prostate cancer improved overall survival (hazard ratio 0.70, 95 percent confidence interval 0.57 to 0.85...

  Prostate cancerLocalised prostate cancer, high and very high riskBicalutamideBuserelin
• 2015IBIS-I (International Breast Intervention Study I) reported

  Breast cancer in 251 of the tamoxifen arm against 350 of the placebo arm at a median 16 years, hazard ratio 0.71, with no difference in breast cancer mortality (Lancet Oncology 201...

  Breast cancer (all types)Tamoxifen
• 2015JCOG0403 reported

  3-year overall survival 76.5% (operable) and 59.9% (inoperable) after 48 Gy in 4 fractions.

  Non-small-cell lung cancerResectable stage I to III non-small-cell lung cancer
• 2015KEYNOTE-006 reported

  10-year OS 34.0% vs 23.6%.

  MelanomaAdvanced melanoma (unresectable stage III and stage IV)PembrolizumabIpilimumab
• 2015NCIC MA.20 reported

  10-year disease-free survival 82.0% vs 77.0% (hazard ratio 0.76); overall survival unchanged.

  HR-positive / HER2-negative breast cancerHER2-positive breast cancerTriple-negative breast cancer (TNBC)Breast cancer (all types)
• 2015Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases reported
  Brain metastases (secondary brain tumours)Temozolomide
• 2015PRIME II reported

  10-year local recurrence 9.5% (no radiotherapy) vs 0.9% (radiotherapy); no difference in survival.

  HR-positive / HER2-negative breast cancerBreast cancer (all types)
• 2015RAISE reported

  Median overall survival 13.3 against 11.7 months.

  Colorectal cancerRamucirumabFOLFIRI (5-FU, leucovorin, irinotecan)
• 2015RECOURSE reported

  Median overall survival 7.1 against 5.3 months (hazard ratio 0.68).

  Colorectal cancerTrifluridine/tipiracil
• 2015RESONATE-2 reported

  Ibrutinib improved progression-free and overall survival over chlorambucil in older patients with untreated CLL; approved for first-line CLL in March 2016.

  Chronic lymphocytic leukaemia, first treatmentChronic lymphocytic leukaemiaIbrutinibChlorambucil
• 2015RESPONSE reported

  Composite response at week 32: 21% vs 1%; haematocrit control 60% vs 20%.

  Polycythaemia vera (PV)Myeloproliferative neoplasms (PV, ET, myelofibrosis)RuxolitinibPipobroman
• 2015RTOG 0617 reported

  Median overall survival 28.7 months (60 Gy) vs 20.3 months (74 Gy); cetuximab no benefit.

  Non-small-cell lung cancerCetuximabCarboplatinPaclitaxel / nab-paclitaxel
• 2015Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly reported
  Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinomaPasireotideSomatostatin analogues (octreotide, lanreotide)
• 2015SELECT reported

  PFS 18.3 vs 3.6 months; HR 0.21.

  Thyroid cancer
• 2015SQUIRE reported

  Overall survival significantly longer with necitumumab added to gemcitabine and cisplatin, by roughly six weeks at the median; hypomagnesaemia, rash and thromboembolism were the ad...

  Squamous cell carcinoma of the lungNon-small-cell lung cancerNecitumumabGemcitabine
• 2015STARS and ROSEL pooled analysis reported

  Pooled three-year overall survival 95 percent with stereotactic radiotherapy against 79 percent with surgery (hazard ratio 0.14, p=0.037) in 58 patients; recurrence-free survival n...

  Resectable stage I to III non-small-cell lung cancer
• 2015Study 3 (rolapitant, moderately emetogenic chemotherapy) reported

  Delayed-phase complete response 71% vs 62% with active control (odds ratio 1.6, 95% CI 1.2 to 2.0; p = 0.0002).

  RolapitantGranisetronDexamethasone
• 2015SWOG S0809 reported

  2-year OS 65% (R0 67%, R1 60%); median OS 35 months; grade 3 and 4 toxicity 52% and 11%.

  Gallbladder cancerExtrahepatic cholangiocarcinoma (perihilar and distal)Biliary tract cancer (cholangiocarcinoma)Gemcitabine
• 2015Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma reported
  Mantle cell lymphomaRituximabBortezomibIbritumomab tiuxetan

The publication year on key paper records.

• 2015A Big Bang model of human colorectal tumor growth

  Sottoriva A, Kang H, Ma Z, et al. Nature Genetics.

• 2015A combination of molecular markers and clinical features improve the classification of pancreatic cysts

  Springer S, Wang Y, Dal Molin M, et al. Gastroenterology.

• 2015A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

  Yurkovetskiy AV, Yin M, Bodyak N, et al. Cancer Research.

• 2015A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas

  Basturk O, Hong SM, Wood LD, et al. American Journal of Surgical Pathology.

• 2015Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302)...

  Ryan CJ, Smith MR, Fizazi K, et al. The Lancet Oncology.

• 2015Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

  Thress KS, Paweletz CP, Felip E, et al. Nature Medicine.

• 2015Acute lymphoblastic leukaemia in children (review)

  Hunger SP, Mullighan CG. New England Journal of Medicine.

• 2015Acute Myeloid Leukemia

  Döhner H, Weisdorf DJ, Bloomfield CD. New England Journal of Medicine.

• 2015Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

  Early Breast Cancer Trialists' Collaborative Group (EBCTCG). The Lancet.

• 2015Adjuvant ovarian suppression in premenopausal breast cancer

  Francis PA, Regan MM, Fleming GF, et al. New England Journal of Medicine.

• 2015AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse

  Moskowitz CH, Nademanee A, Masszi T, et al. The Lancet.

• 2015Androgen receptor: structure, role in prostate cancer and drug discovery

  Tan MH, Li J, Xu HE, et al. Acta pharmacologica Sinica.

• 2015APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer

  Tolaney SM, Barry WT, Dang CT, et al. New England Journal of Medicine.

• 2015Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  Valtorta E, Martino C, Sartore-Bianchi A, et al. Modern Pathology.

• 2015AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts

  Dombret H, Seymour JF, Butrym A, et al. Blood.

• 2015BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma

  Migden MR, Guminski A, Gutzmer R, et al. The Lancet Oncology.

• 2015Building a global consensus approach to chordoma: a position paper from the medical and patient community

  Stacchiotti S, Sommer J, Chordoma Global Consensus Group. The Lancet Oncology.

• 2015Cancer across the tree of life: cooperation and cheating in multicellularity

  Aktipis CA, Boddy AM, Jansen G, et al. Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

• 2015Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions

  Tomasetti C, Vogelstein B. Science.

• 2015Carcinogenicity of consumption of red and processed meat

  Bouvard V, Loomis D, Guyton KZ, et al. The Lancet Oncology.

• 2015Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

  Stewart AK, Rajkumar SV, Dimopoulos MA, et al. New England Journal of Medicine.

• 2015CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

  Maude SL, Teachey DT, Porter DL, et al. Blood.

• 2015CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer

  Sweeney CJ, Chen YH, Carducci M, et al. New England Journal of Medicine.

• 2015Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms

  Heetfeld M, Chougnet CN, Olsen IH, et al. Endocrine-related cancer.

• 2015CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy

  Brahmer J, Reckamp KL, Baas P, et al. New England Journal of Medicine.

• 2015CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer

  Borghaei H, Paz-Ares L, Horn L, et al. New England Journal of Medicine.

• 2015Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

  Sausen M, Phallen J, Adleff V, et al. Nature Communications.

• 2015Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

  Skoulidis F, Byers LA, Diao L, et al. Cancer Discovery.

• 2015COMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma

  Long GV, Stroyakovskiy D, Gogas H, et al. The Lancet.

• 2015Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

  Larkin J, Chiarion-Sileni V, Gonzalez R, et al. New England Journal of Medicine.

• 2015Compliance with results reporting at ClinicalTrials.gov

  Anderson ML, Chiswell K, Peterson ED, et al. New England Journal of Medicine.

• 2015Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer

  Burstein MD, Tsimelzon A, Poage GM, et al. Clinical Cancer Research.

• 2015Comprehensive genomic profiles of small cell lung cancer

  George J, Lim JS, Jang SJ, et al. Nature.

• 2015Dance/movement therapy for improving psychological and physical outcomes in cancer patients

  Bradt J, Shim M, Goodill SW. The Cochrane database of systematic reviews.

• 2015Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications

  McCollough CH, Leng S, Yu L, et al. Radiology.

• 2015Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemo...

  van Waart H, Stuiver MM, van Harten WH, et al. Journal of Clinical Oncology.

• 2015Elective versus therapeutic neck dissection in node-negative oral cancer

  D'Cruz AK, Vaish R, Kapre N, et al. New England Journal of Medicine.

• 2015Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial

  Mao JJ, Bowman MA, Xie SX, et al. Journal of Clinical Oncology.

• 2015Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

  Watson PA, Arora VK, Sawyers CL. Nature Reviews Cancer.

• 2015ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours

  Caplin ME, Baudin E, Ferolla P, et al. Annals of Oncology.

• 2015Expanding global access to radiotherapy

  Atun R, Jaffray DA, Barton MB, et al. The Lancet Oncology.

• 2015Ferlay 2015: sources, methods and major patterns in GLOBOCAN 2012

  Ferlay J, Soerjomataram I, Dikshit R, et al. International Journal of Cancer.

• 2015First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial

  Chawla SP, Papai Z, Mukhametshina G, et al. JAMA Oncology.

• 2015Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs

  Mailankody S, Prasad V. JAMA Oncology.

• 2015FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and m...

  Cremolini C, Loupakis F, Antoniotti C, et al. The Lancet Oncology.

• 2015Genomic spectra of biliary tract cancer

  Nakamura H, Arai Y, Totoki Y, et al. Nature Genetics.

• 2015Glioma

  Weller M, Wick W, Aldape K, et al. Nature reviews. Disease primers.

• 2015Global cancer surgery: delivering safe, affordable, and timely cancer surgery

  Sullivan R, Alatise OI, Anderson BO, et al. The Lancet Oncology.

• 2015Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes

  Castel D, Philippe C, Calmon R, et al. Acta neuropathologica.

• 2015Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

  Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Trends in molecular medicine.

• 2015IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years

  Cuzick J, Sestak I, Cawthorn S, et al. Lancet Oncology.

• 2015Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

  Burger JA, Tedeschi A, Barr PM, et al. New England Journal of Medicine.

• 2015Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on path...

  Sikov WM, Berry DA, Perou CM, et al. Journal of Clinical Oncology.

• 2015Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer

  Couch FJ, Hart SN, Sharma P, et al. Journal of Clinical Oncology.

• 2015Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer

  Poortmans PM, Collette S, Kirkove C, et al. New England Journal of Medicine.

• 2015Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy

  Riley P, Glenny AM, Worthington HV, et al. The Cochrane database of systematic reviews.

• 2015JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

  Kleppe M, Kwak M, Koppikar P, et al. Cancer Discovery.

• 2015KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off

  Garon EB, Rizvi NA, Hui R, et al. New England Journal of Medicine.

• 2015KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma

  Robert C, Schachter J, Long GV, et al. New England Journal of Medicine.

• 2015Laetrile treatment for cancer

  Milazzo S, Horneber M. The Cochrane database of systematic reviews.

• 2015Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ

  Le DT, Uram JN, Wang H, et al. New England Journal of Medicine.

• 2015Long-term follow-up of a large active surveillance cohort of patients with prostate cancer (Sunnybrook)

  Klotz L, Vesprini D, Sethukavalan P, et al. Journal of Clinical Oncology.

• 2015Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hy...

  Glaser DA, Hossain P, Perkins W, et al. The British journal of dermatology.

• 2015Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

  Herbst RS, Gandara DR, Hirsch FR, et al. Clinical Cancer Research.

• 2015Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones

  Martincorena I, Roshan A, Gerstung M, et al. Science.

• 2015Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  Spranger S, Bao R, Gajewski TF. Nature.

• 2015MET exon 14 splicing alterations across tumour types and their sensitivity to MET inhibitors

  Frampton GM, Ali SM, Rosenzweig M, et al. Cancer Discovery.

• 2015Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

  Chang CH, Qiu J, O'Sullivan D, et al. Cell.

• 2015Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcom...

  Bielack SS, Smeland S, Whelan JS, et al. Journal of Clinical Oncology.

• 2015Molecular and cellular insights into T cell exhaustion

  Wherry EJ, Kurachi M. Nature reviews. Immunology.

• 2015Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity

  Knowles MA, Hurst CD. Nature Reviews Cancer.

• 2015Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

  Pajtler KW, Witt H, Sill M, et al. Cancer Cell.

• 2015Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

  Garcia-Murillas I, Schiavon G, Weigelt B, et al. Science Translational Medicine.

• 2015Nivolumab in previously untreated melanoma without BRAF mutation

  Robert C, Long GV, Brady B, et al. New England Journal of Medicine.

• 2015OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus

  Andtbacka RH, Kaufman HL, Collichio F, et al. Journal of Clinical Oncology.

• 2015PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  Patel SP, Kurzrock R. Molecular Cancer Therapeutics.

• 2015Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy

  Amant F, Vandenbroucke T, Verheecke M, et al. New England Journal of Medicine.

• 2015PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor

  Wang K, Zhang Q, Li D, et al. Clinical Cancer Research.

• 2015Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution C...

  Kim YH, Tavallaee M, Sundram U, et al. Journal of Clinical Oncology.

• 2015Prasad: most surrogate endpoints in cancer trials correlate poorly with survival

  Prasad V, Kim C, Burotto M, Vandross A. JAMA Internal Medicine.

• 2015PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers

  Toledo E, Salas-Salvadó J, Donat-Vargas C, et al. JAMA Internal Medicine.

• 2015Prognostic significance of POLE proofreading mutations in endometrial cancer

  Church DN, Stelloo E, Nout RA, et al. JNCI: Journal of the National Cancer Institute.

• 2015Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study...

  Nagata Y, Hiraoka M, Shibata T, et al. International Journal of Radiation Oncology, Biology, Physics.

• 2015PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate

  Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. European Urology.

• 2015Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

  Field KM, Simes J, Nowak AK, et al. Neuro-Oncology.

• 2015Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)

  Mayer RJ, Van Cutsem E, Falcone A, et al. New England Journal of Medicine.

• 2015RAPID: PET-directed therapy for early-stage Hodgkin lymphoma

  Radford J, Illidge T, Counsell N, et al. New England Journal of Medicine.

• 2015Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

  Smith TJ, Bohlke K, Lyman GH, et al. Journal of Clinical Oncology.

• 2015Regional Nodal Irradiation in Early-Stage Breast Cancer

  Whelan TJ, Olivotto IA, Parulekar WR, et al. New England Journal of Medicine.

• 2015Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma

  Wells SA, Asa SL, Dralle H, et al. Thyroid.

• 2015Revised International Staging System (R-ISS) for multiple myeloma

  Palumbo A, Avet-Loiseau H, Oliva S, et al. Journal of Clinical Oncology.

• 2015Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States

  Frazier AL, Hale JP, Rodriguez-Galindo C, et al. Journal of Clinical Oncology.

• 2015Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer

  Rizvi NA, Hellmann MD, Snyder A, et al. Science.

• 2015Rolapitant for prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens: a...

  Schwartzberg LS, Modiano MR, Rapoport BL, et al. The Lancet Oncology.

• 2015Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2...

  Topp MS, Gökbuget N, Stein AS, et al. The Lancet Oncology.

• 2015Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma

  Scanu T, Spaapen RM, Bakker JM, et al. Cell Host and Microbe.

• 2015SELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer

  Schlumberger M, Tahara M, Wirth LJ, et al. New England Journal of Medicine.

• 2015Siegel 2015: Cancer statistics, 2015

  Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.

• 2015Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell line...

  English DP, Bellone S, Schwab CL, et al. Cancer.

• 2015Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with...

  Bradley JD, Paulus R, Komaki R, et al. The Lancet Oncology.

• 2015STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma

  Bruix J, Takayama T, Mazzaferro V, et al. The Lancet Oncology.

• 2015Stromal contribution to the colorectal cancer transcriptome

  Isella C, Terrasi A, Bellomo SE, et al. Nature Genetics.

• 2015Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

  Calon A, Lonardo E, Berenguer-Llergo A, et al. Nature Genetics.

• 2015SU2C-PCF: integrative clinical genomics of advanced prostate cancer

  Robinson D, Van Allen EM, Wu YM, et al. Cell.

• 2015Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location

  Lee H, Choi DW, Park JY, et al. Annals of Surgical Oncology.

• 2015Surviving at a Distance: Organ-Specific Metastasis

  Obenauf AC, Massagué J. Trends in cancer.

• 2015SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangioc...

  Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. Journal of Clinical Oncology.

• 2015Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

  Di Maio M, Gallo C, Leighl NB, et al. Journal of Clinical Oncology.

• 2015Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

  Ashkenazi A. Journal of Clinical Investigation.

• 2015TCGA: the molecular taxonomy of primary prostate cancer

  Cancer Genome Atlas Research Network. Cell.

• 2015The consensus molecular subtypes of colorectal cancer

  Guinney J, Dienstmann R, Wang X, et al. Nature Medicine.

• 2015The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positiv...

  Finn RS, Crown JP, Lang I, et al. The Lancet Oncology.

• 2015The Economics of Reproducibility in Preclinical Research

  Freedman LP, Cockburn IM, Simcoe TS. PLoS biology.

• 2015The evolutionary history of lethal metastatic prostate cancer

  Gundem G, Van Loo P, Kremeyer B, et al. Nature.

• 2015The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer

  Villarreal-Garza C, Weitzel JN, Llacuachaqui M, et al. Breast Cancer Research and Treatment.

• 2015Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

  Byrd JC, Furman RR, Coutre SE, et al. Blood.

• 2015Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Girard N, Ruffini E, Marx A, et al. Annals of Oncology.

• 2015TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer

  Mateo J, Carreira S, Sandhu S, et al. New England Journal of Medicine.

• 2015Torre 2015: Global cancer statistics, 2012

  Torre LA, Bray F, Siegel RL, et al. CA: A Cancer Journal for Clinicians.

• 2015Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations

  Rozhok AI, DeGregori J. Proceedings of the National Academy of Sciences.

• 2015Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study

  Shindoh J, de Aretxabala X, Aloia TA, et al. Annals of Surgery.

• 2015Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

  Hyman DM, Puzanov I, Subbiah V, et al. New England Journal of Medicine.

• 2015Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

  Moffitt RA, Marayati R, Flate EL, et al. Nature Genetics.

• 2015Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)

  Robinson GW, Orr BA, Wu G, et al. Journal of Clinical Oncology.

• 2015Whole genomes redefine the mutational landscape of pancreatic cancer

  Waddell N, Pajic M, Patch AM, et al. Nature.

• 2015Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

  Witkiewicz AK, McMillan EA, Balaji U, et al. Nature Communications.

The history entries editors wrote on cancer records: the dated turning points of each disease.

• 2015ACNS0122: chemotherapy then craniospinal irradiation for non-germinomatous tumours

  Central nervous system germ cell tumours (germinoma and non-germinomatous). Goldman and colleagues (JCO).

  CarboplatinEtoposideIfosfamide
• 2015AETHERA: brentuximab consolidation after transplant

  Hodgkin lymphoma

  AETHERA
• 2015AETHERA: brentuximab vedotin consolidation after transplant lengthens progression-free survival

  Relapsed and refractory classical Hodgkin lymphoma

  AETHERABrentuximab vedotin
• 2015Anastrozole versus tamoxifen for DCIS (NSABP B-35, IBIS-II DCIS)

  Ductal carcinoma in situ (DCIS). Aromatase inhibitor an alternative in postmenopausal women.

  Tamoxifen
• 2015ANGIOTAX-PLUS: adding bevacizumab to paclitaxel does not improve outcomes

  Angiosarcoma

  Paclitaxel / nab-paclitaxelBevacizumab
• 2015APT: de-escalation for small tumours

  HER2-positive breast cancer

  APT (adjuvant paclitaxel-trastuzumab)
• 2015ATA guideline: codon-based timing of prophylactic thyroidectomy

  Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)

  Thyroid cancer
• 2015BALLAD opens as an international trial of adjuvant chemotherapy versus observation

  Localised small bowel adenocarcinoma (stage I to III, resected)

• 2015Baltimore consensus separates associated from concomitant carcinoma

  Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)

  Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer
• 2015Baltimore consensus: precursor lesions graded low or high

  Pancreatic ductal adenocarcinoma. PanIN, IPMN and MCN move to a two-tier grading; 0.5 to 1 cm separates a large PanIN from an incipient IPMN.

  Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancerHigh-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)
• 2015Biliary subtypes separated molecularly

  Gallbladder cancer. 260 Japanese biliary cancers: FGFR2 fusions intrahepatic, APOBEC signature and ELF3 in gallbladder and extrahepatic tumours (Nakamura et al., Nature Genetics).

  Genomic spectra of biliary tract cancerELF3
• 2015BOLT: sonidegib approved

  Locally advanced and metastatic basal cell carcinoma

  BOLTSonidegib
• 2015CHAARTED and STAMPEDE: docetaxel at first metastatic diagnosis

  Prostate cancer

  CHAARTED (E3805)STAMPEDE
• 2015CHAARTED: docetaxel with hormone therapy lengthens life

  Metastatic hormone-sensitive prostate cancer

  CHAARTED (E3805)Docetaxel
• 2015CheckMate 067 combination and KEYNOTE-006; T-VEC first oncolytic virus; cobimetinib

  Melanoma

  CheckMate 067KEYNOTE-006Talimogene laherparepvecCobimetinib
• 2015CheckMate 067: nivolumab plus ipilimumab; T-VEC first oncolytic virus

  Advanced melanoma (unresectable stage III and stage IV)

  CheckMate 067Talimogene laherparepvec
• 2015Chordoma Global Consensus Group

  Chordoma. First international recommendations on surgery, radiotherapy and systemic therapy (Lancet Oncol).

• 2015Daratumumab approved

  Multiple myeloma

• 2015Daratumumab, the first CD38 antibody, approved for heavily pretreated myeloma

  Relapsed or refractory multiple myeloma

  Daratumumab
• 2015Daratumumab: first CD38 antibody; R-ISS published

  Multiple myeloma

  DaratumumabR-ISS / R2-ISS staging
• 2015Dinutuximab approved (US); dinutuximab beta in EU 2017

  Neuroblastoma (paediatric)

  Dinutuximab (ch14.18) / dinutuximab beta
• 2015Dinutuximab approved for high-risk neuroblastoma

  Childhood cancers (all types). Anti-GD2 antibody added to maintenance therapy after the Children's Oncology Group trial.

  Dinutuximab (ch14.18) / dinutuximab beta
• 2015Dinutuximab approved for high-risk neuroblastoma

  High-risk neuroblastoma

  Dinutuximab (ch14.18) / dinutuximab beta
• 2015Elective neck dissection improves survival in early oral cancer

  Buccal mucosa and gingivobuccal cancer (oral cancer in India)

  Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)
• 2015Elective neck dissection improves survival in early oral cancer (Tata Memorial)

  Oral cavity cancer (mouth and tongue)

• 2015EORTC 18071: adjuvant ipilimumab improves relapse-free and overall survival at high toxicity

  Stage III melanoma (after surgery)

  Ipilimumab
• 2015First dramatic response to BRAF/MEK inhibition in papillary craniopharyngioma

  Craniopharyngioma. Case report (JNCI) leads to the Alliance A071601 trial.

  Dabrafenib + trametinib
• 2015Four consensus subtypes, and the discovery that the worst one is stroma

  Colorectal cancer. The consensus molecular subtypes reconcile six classifications across 4,151 samples; two papers published together show the mesenchymal signal comes from fibrobl...

  The consensus molecular subtypes of colorectal cancerStromal contribution to the colorectal cancer transcriptomeStromal gene expression defines poor-prognosis subtypes in colorectal cancerAssessment of a HER2 scoring system for colorectal cancer: results from a validation study
• 2015Germline testing case made for all triple-negative disease

  Triple-negative breast cancer (TNBC). 14.6 percent of 1,824 unselected triple-negative patients carry a predisposition mutation, 11.2 percent in BRCA1 or BRCA2 (Couch, JCO); the sa...

  Germline BRCA testing criteria for triple-negative breast cancer (UK)BRCA-associated triple-negative breast cancerInherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancerComprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer
• 2015Heetfeld and colleagues characterise well-differentiated grade 3 tumours as distinct from carcinoma

  Grade 3 well-differentiated neuroendocrine tumour

• 2015Hepatic-side T2 tumours shown to behave worse

  Gallbladder cancer. Shindoh and colleagues' international series (437 patients) separates peritoneal-side from hepatic-side T2 disease: five-year survival 42.6 versus 64.7 percent.

  T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study
• 2015Ibrutinib: first drug ever approved for WM

  Waldenström macroglobulinaemia

  Ibrutinib
• 2015KEYNOTE-001: PD-L1 expression predicts pembrolizumab response in lung cancer

  PD-L1-high non-small-cell lung cancer without a driver mutation

  PembrolizumabKEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-offTumour proportion score (TPS)
• 2015Le and Diaz show PD-1 blockade works in mismatch repair deficient tumours of any site

  Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma

  PembrolizumabDung T. Le
• 2015Le and Diaz: PD-1 blockade works in mismatch-repair deficient tumours (NEJM)

  Mismatch-repair deficient (MSI-high) colorectal cancer

  PembrolizumabLuis A. Diaz Jr.
• 2015Lenvatinib approved (SELECT)

  Papillary thyroid cancer

  Lenvatinib
• 2015Lenvatinib approved (SELECT); ATA guidelines endorse active surveillance and less radioiodine

  Thyroid cancer

  SELECTActive surveillance of papillary microcarcinoma
• 2015Linsitinib phase 3 fails: IGF-1 receptor blockade does not work

  Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)

• 2015MaGIC pooled risk classification

  Germ cell tumours of childhood and adolescence (extracranial and CNS). Frazier and colleagues (JCO) combine COG and CCLG data to define shared risk groups.

• 2015MED12 and TERT promoter mutations mapped across fibroepithelial tumours

  Phyllodes tumour of the breast

• 2015MET exon 14 skipping shown to be a targetable driver with crizotinib responses

  MET exon 14 and MET-amplified non-small-cell lung cancer

  METCrizotinib
• 2015Mismatch repair deficiency predicts response to PD-1 blockade

  Colorectal cancer. Four of 10 deficient colorectal cancers responded to pembrolizumab and none of 18 proficient ones, with a mean of 1,782 against 73 mutations per tumour.

  Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organMSI-high (microsatellite instability by PCR or sequencing)
• 2015Molecular landscape of SBA published

  Small intestine cancer (small bowel adenocarcinoma). Schrock and colleagues (JAMA Oncol 2017) later show SBA is genomically distinct from colorectal and gastric cancer, with freque...

• 2015Nicotinamide reduces new keratinocyte cancers (ONTRAC, NEJM)

  Basal cell carcinoma

• 2015Nine molecular groups across the neuraxis

  Ependymoma. Pajtler and colleagues (Cancer Cell) define the methylation-based classification later adopted by WHO.

  DNA methylation profiling
• 2015Nivolumab approved: immunotherapy enters lung cancer

  Lung cancer (all types)

  Nivolumab
• 2015Nivolumab beats docetaxel: immunotherapy era

  Non-small-cell lung cancer. CheckMate 017/057; pembrolizumab first line for PD-L1 ≥50% follows (KEYNOTE-024, 2016).

  NivolumabPembrolizumabKEYNOTE-024 & KEYNOTE-189
• 2015Nivolumab beats everolimus (CheckMate 025): immunotherapy returns to RCC

  Renal cell carcinoma

  Nivolumab
• 2015Nivolumab beats everolimus after anti-angiogenic therapy (CheckMate 025)

  Clear cell renal cell carcinoma

  Nivolumab
• 2015Osimertinib approved for T790M resistance after first-generation inhibitors

  EGFR-mutated non-small-cell lung cancer

  Osimertinib
• 2015Palbociclib: first CDK4/6 inhibitor

  HR-positive / HER2-negative breast cancer

  PalbociclibPALOMA-2
• 2015PBTC-025B and 032: vismodegib responses confined to SHH tumours with upstream lesions

  SHH-activated medulloblastoma

  Vismodegib
• 2015Pexidartinib phase 1 responses

  Tenosynovial giant cell tumour (TGCT). Tap and colleagues, NEJM: high response rate in diffuse TGCT.

  Pexidartinib
• 2015ProMisE classifier reproduces the TCGA classes with clinical tests

  POLE-ultramutated endometrial cancer

• 2015RAPID: PET-negative patients can omit radiotherapy at a small cost in relapse

  Early-stage classical Hodgkin lymphoma (stage I to II)

  PET-adapted (response-adapted) therapyDeauville five-point scale
• 2015Registry defines types I to III and treatment recommendations

  Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours). Messinger and colleagues (Cancer 2015) report outcomes by type.

• 2015RTOG 0617: 74 Gy is worse than 60 Gy; dose escalation abandoned

  Unresectable stage III non-small-cell lung cancer

  IMRT / IGRT (modern external beam)NRG Oncology
• 2015Sequencing studies show that KRAS wild-type pancreatic cancers are enriched for alternative drivers

  KRAS wild-type pancreatic ductal adenocarcinoma

  Comprehensive genomic profilingKRAS
• 2015Sonidegib approved (BOLT)

  Basal cell carcinoma

  Sonidegib
• 2015STORM: adjuvant sorafenib fails after resection or ablation

  Early hepatocellular carcinoma (BCLC 0 and A)

  Sorafenib
• 2015Sunitinib active in thymic carcinoma (Thomas, Lancet Oncol)

  Thymoma and thymic carcinoma

  Sunitinib
• 2015Sunitinib phase 2 reports responses in thymic carcinoma after platinum

  Thymic carcinoma

  Sunitinib
• 2015SWOG S0809: the only prospective adjuvant chemoradiation trial

  Gallbladder cancer. 79 patients, two-year survival 65 percent; no randomised trial has followed.

  SWOG S0809SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
• 2015T-VEC: first oncolytic virus

  Melanoma

  Talimogene laherparepvec
• 2015TARPSWG consensus on management of primary retroperitoneal sarcoma

  Retroperitoneal sarcoma

• 2015Tata Memorial: elective neck dissection improves survival in early oral cancer

  Oral tongue and floor of mouth cancer

  Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)
• 2015The genome is classified, and DNA repair becomes a target

  Prostate cancer. TCGA put 74 percent of 333 primary tumours into seven subtypes and found DNA repair inactivation in 19 percent; the Stand Up To Cancer cohort sequenced 150 metasta...

  TCGA: the molecular taxonomy of primary prostate cancerSU2C-PCF: integrative clinical genomics of advanced prostate cancerTOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancerThe evolutionary history of lethal metastatic prostate cancer
• 2015The small-cell genome, and mutation load as a predictor

  Non-small-cell lung cancer. Biallelic TP53 and RB1 loss in nearly all of 110 small-cell genomes, with NOTCH inactivation in 25%; in the same year, non-synonymous mutation burden is...

  Comprehensive genomic profiles of small cell lung cancerRizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancerCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesRB1
• 2015TIGER trial opens

  Extragonadal germ cell tumour. The Alliance and European groups randomise first-relapse germ cell tumours between conventional-dose TIP and high-dose TI-CE with stem cell rescue, t...

  TIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours
• 2015Treatment of lichen sclerosus with topical steroids associated with fewer vulvar cancers in a prospective cohort

  HPV-independent vulvar squamous cell carcinoma (p53-mutant)

• 2015Trifluridine/tipiracil approved for refractory disease

  Colorectal cancer. RECOURSE established the oral combination after fluoropyrimidine, oxaliplatin, irinotecan and the antibodies had run out.

  Trifluridine/tipiracilRECOURSE
• 2015TTFields improves OS (EF-14)

  Glioma & glioblastoma

  Optune / Optune Pax (TTFields)
• 2015Vemurafenib active in relapsed HCL

  Hairy cell leukaemia

  Vemurafenib
• 2015WHO lung classification groups carcinoids with small-cell and large-cell neuroendocrine carcinoma as neuroendocrine tumours

  Lung neuroendocrine tumours (typical and atypical carcinoid)

  Neuroendocrine tumour grade (Ki-67) and WHO classification
• 2015Whole genomes and the classical versus basal-like split

  Pancreatic ductal adenocarcinoma. Waddell's 100 genomes tie unstable genomes to BRCA-type defects and platinum response; Moffitt separates tumour from stroma and finds two tumour a...

  Whole genomes redefine the mutational landscape of pancreatic cancerVirtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

The since year on technology records: first use in humans or first approval, as the record states it.

• 2015CDK4/6 inhibitors

  First use in humans or first approval, as the technology record states it.

• 2015Oncolytic viruses

  First use in humans or first approval, as the technology record states it.

• 2015Radiotherapy access and the global machine gap

  First use in humans or first approval, as the technology record states it.

• 2015Scalp cooling (cold caps: DigniCap, Paxman)

  First use in humans or first approval, as the technology record states it.

The founded year on company records.

• 2015Actuate Therapeutics founded

  Fort Worth, Texas, United States

• 2015Arcus Biosciences founded

  Hayward

• 2015Bolt Biotherapeutics founded

  Redwood City, California

• 2015Color Health founded

  South San Francisco, CA

• 2015CStone Pharmaceuticals founded

  Suzhou / Shanghai

• 2015ExCellThera founded

  Montreal

• 2015Forward Pharmaceuticals founded

  Shenzhen

• 2015Hangzhou Sumgen Biotech founded

  Hangzhou

• 2015Hummingbird Bioscience founded

  Singapore

• 2015InnoCare Pharma founded

  Beijing

• 2015Keros Therapeutics founded

  Lexington, Massachusetts

• 2015Neutron Therapeutics founded

  Danvers, MA

• 2015ONK Therapeutics founded

  Galway

• 2015Shanghai Miracogen founded

  Shanghai

• 2015Strata Oncology founded

  Ann Arbor, Michigan, United States

• 2015Tmunity Therapeutics founded

  Philadelphia, PA

• 2015Unicar-Therapy founded

  Shanghai

The founded year on journal records.

• 2015JAMA Oncology founded

  American Medical Association (JAMA Network)

• 2015JMIR cancer founded

  JMIR Publications

• 2015Trends in cancer founded

  Cell Press (Elsevier)

The selected publications each biography lists, which is a reading of that person rather than a reading of the year.

• 2015A prospective epidemiological study on odontogenic tumours in a black African population, with emphasis on the relative frequency of ameloblastoma

  International Journal of Oral and Maxillofacial Surgery

• 2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the ESMO Magnitude...

  Annals of Oncology

• 2015AACR Cancer Progress Report 2015

  Clinical Cancer Research

• 2015Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMat...

  The Lancet Oncology

• 2015Acute lymphoblastic leukemia in children

  NEJM

• 2015Acute myeloid leukaemia: challenges and real world data from India

  British Journal of Haematology

• 2015Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Resul...

  Journal of Clinical Oncology

• 2015Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatc...

  J Clin Oncol

• 2015Adjuvant ovarian suppression in premenopausal breast cancer (SOFT)

  NEJM

• 2015Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

  New England Journal of Medicine

  Eric P. Winer
• 2015Advances in Wilms tumor treatment and biology: progress through international collaboration

  JCO

• 2015Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

  Lancet

• 2015Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study

  Annals of Oncology

• 2015Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  Clinical Cancer Research

• 2015Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network

  Geburtshilfe und Frauenheilkunde

• 2015Cancer care in Jordan

  Hematology/Oncology and Stem Cell Therapy

• 2015Cancer stem cells in glioblastoma

  Genes & Development

• 2015CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

  Clinical Cancer Research

• 2015Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification

  Journal of Cancer Research and Clinical Oncology

• 2015Chemohormonal therapy in metastatic hormone-sensitive prostate cancer (CHAARTED)

  NEJM

• 2015Childhood acute lymphoblastic leukemia: progress through collaboration

  JCO

• 2015Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006)

  Lancet Oncology

• 2015Clinical implications of the intrinsic molecular subtypes of breast cancer

  The Breast

• 2015Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma

  Br J Cancer

• 2015Clinical Relevance of KRAS -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy

  Clinical Cancer Research

• 2015Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer

  Biomaterials

• 2015Combined nivolumab and ipilimumab or monotherapy in untreated melanoma (CheckMate 067)

  NEJM

• 2015Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

  Science

• 2015Comprehensive genomic characterization of head and neck squamous cell carcinomas

  Nature

• 2015Concentrating childhood cancer treatment in the Netherlands

  Pädiatrie & Pädologie

• 2015Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer

  PLOS ONE

• 2015Defining and treating high-risk multiple myeloma

  Leukemia

• 2015Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology

• 2015DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer

  Nature Communications

• 2015DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

  New England Journal of Medicine

• 2015Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

  European Journal of Nuclear Medicine and Molecular Imaging

• 2015Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids

  Nature Medicine

• 2015Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial

  Lancet Oncology

• 2015Effect of Neoadjuvant Chemotherapy on the Surgical Treatment of Patients With Locally Advanced Breast Cancer Requiring Initial Mastectomy

  Clinical Breast Cancer

• 2015Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer

  Cancer

• 2015Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast can...

  Lancet Oncology

• 2015EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey

  J Thorac Oncol

• 2015Electronic consultation as an essential implement for Continuity of Care

  International Journal of Integrated Care

• 2015Erste zielgerichtete Therapie bei Ovarialkarzinom für BRCA1/2-Mutationsträgerinnen zugelassen

  Medizinische Genetik

• 2015Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

  Journal of Clinical Oncology

• 2015Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

  Nature Genetics

• 2015Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

  Journal of Clinical Oncology

• 2015Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced no...

  Annals of Oncology

• 2015Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia

  Cancer Cell

• 2015Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia

  European Journal of Haematology

• 2015Gender differences in outcome and use of resources do exist in Swedish intensive care, but to no advantage for women of premenopausal age

  Critical Care

• 2015Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

  Nature

• 2015Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study

  The Lancet Respiratory Medicine

• 2015Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA

  Nature Communications

• 2015Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  Science

• 2015Germline Mutations in Predisposition Genes in Pediatric Cancer

  New England Journal of Medicine

• 2015Graft-versus-host disease versus graft-versus-leukemia

  Hematology

• 2015High numbers of macrophages, especially M2‐like ( CD 163‐positive), correlate with hyaluronan accumulation and poor outcome in breast cancer

  Histopathology

• 2015Hope in Cancer Patients: The Relational Domain as a Crucial Factor

  Tumori Journal

• 2015Human papillomaviruses: shared and distinct pathways for pathogenesis

  Current Opinion in Virology

• 2015Ibrutinib in previously treated Waldenström's macroglobulinemia

  NEJM

• 2015Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer

  Cancer Research

• 2015IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells

  Sci Rep

• 2015Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

  Cell

• 2015Improved overall survival in melanoma with combined dabrafenib and trametinib (COMBI-v)

  NEJM

• 2015In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer

  Nature Genetics

• 2015Inactivating mutations in GNA13 and RHOA in Burkitt’s lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells

  Oncogene

• 2015Integrative clinical genomics of advanced prostate cancer

  Cell

• 2015KRAS as a Therapeutic Target

  Clinical Cancer Research

• 2015Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT)

  NEJM

• 2015Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation

  Blood

• 2015Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

  The Lancet Oncology

• 2015Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer

  Oncotarget

• 2015Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Gr...

  Journal of Clinical Oncology

• 2015Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis

  Leukemia & Lymphoma

• 2015Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology

• 2015Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clini...

  Journal of Molecular Diagnostics

• 2015Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

  Nature Communications

• 2015Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

  Nature

• 2015Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia

  Nature Medicine

• 2015Modeling Signaling Networks to Advance New Cancer Therapies

  Annual Review of Biomedical Engineering

• 2015Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA)

  Lancet Oncology

• 2015MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50–75 Years with Extremely Dense Breasts: The DENSE Trial Study...

  Radiology

• 2015Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable...

  Journal of Clinical Oncology

• 2015Multiple myeloma

  Lancet

• 2015Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  Science

• 2015Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

  The Lancet Oncology

  J. Jan B. van Lanschot
• 2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised...

  Lancet Oncology

• 2015Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials

  Current Colorectal Cancer Reports

• 2015Neoantigens in cancer immunotherapy

  Science

• 2015Neuronal activity promotes glioma growth through neuroligin-3 secretion

  Cell

• 2015Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (CheckMate 069)

  NEJM

• 2015Nivolumab in previously untreated melanoma without BRAF mutation (CheckMate 066)

  NEJM

• 2015Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

  New England Journal of Medicine

• 2015Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

  Lancet Oncology

• 2015Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

  Cancer Research

• 2015Oncolytic viruses: a new class of immunotherapy drugs

  Nature Reviews Drug Discovery

• 2015Organoid models of human and mouse ductal pancreatic cancer

  Cell

• 2015Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial

  Journal of Clinical Oncology

• 2015PD-1 blockade in tumors with mismatch-repair deficiency

  New England Journal of Medicine

  Dung T. Le
• 2015Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006)

  NEJM

• 2015Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA)

  NEJM

• 2015Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

  Annals of Oncology

• 2015PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion

  Proceedings of the National Academy of Sciences

• 2015Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer

  Journal of Oncology Practice

• 2015Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis

  The Lancet Haematology

• 2015Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

  Cancer Treatment Reviews

• 2015Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology

• 2015Providing incentives to share data early in health emergencies: the role of journal editors

  Lancet

• 2015Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell...

  Journal of Clinical Oncology

• 2015Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

  Nature Medicine

• 2015Recurrent CDKN1B (p27) mutations in hairy cell leukemia

  Blood

• 2015Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant pr...

  Haematologica

• 2015Regional nodal irradiation in early-stage breast cancer (MA.20)

  NEJM

• 2015Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

  OncoImmunology

• 2015Reserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tract

  Science Signaling

• 2015Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

  Annals of Oncology

• 2015Risk factors for glioblastoma therapy associated complications

  Clinical Neurology and Neurosurgery

• 2015RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

  Cancer Cell

• 2015Role of Local Radiation Therapy in Cancer Immunotherapy

  JAMA Oncology

• 2015Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

  Journal of Clinical Oncology

• 2015Solitary, multiple, benign, atypical, or malignant: the “Granular Cell Tumor” puzzle

  Virchows Archiv

• 2015Somatic mutations and clonal hematopoiesis in aplastic anemia

  New England Journal of Medicine

• 2015Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

  Lancet Oncology

• 2015Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy

  Nature Reviews Clinical Oncology

• 2015Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study

  Eur J Cancer

• 2015Sustainability and long-term effectiveness of the WHO surgical safety checklist combined with pulse oximetry in a resource-limited setting: two-year update from...

  JAMA Surg

• 2015T cell exclusion, immune privilege, and the tumor microenvironment

  Science

• 2015Talimogene laherparepvec improves durable response rate in patients with advanced melanoma (OPTiM)

  JCO

  Howard L. Kaufman
• 2015Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

  Lancet Oncology

• 2015Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  Nature Medicine

• 2015The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases

  Front Neurol

• 2015The future of immune checkpoint therapy

  Science

• 2015The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis

  Radiother Oncol

• 2015The same, only different – DNA damage checkpoints and their reversal throughout the cell cycle

  Journal of Cell Science

• 2015Update in genetic susceptibility in melanoma

  Ann Transl Med

• 2015Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (...

  J Thorac Oncol

• 2015Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening

  JAMA

• 2015Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy

  Clinical Cancer Research